Prescribing information (external link)
KISQALI® (ribociclib): Patient-centric decision making for HR+/HER2− aBC patients
Indications:1
Advanced breast cancer (aBC)
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).
In pre/perimenopausal women, the ET should be combined with a a luteinising hormone-releasing hormone (LHRH) agonist
KISQALI is not recommended to be used in combination with tamoxifen.
Webinar series to support KISQALI prescribers
Explore this mini-series of on-demand webinars, taking you from a brief overview of the pivotal clinical trials data for KISQALI through to the expert experience of consultants managing HR+/HER2– aBC patients in today’s clinical practice.
Dr Hartmut Kristeleit: Patient case study
Dr Elsa Papadimitraki: Patient case study
Group Panel discussion
Learn more about the safety profile of KISQALI in aBC
Learn more about efficacy in postmenopausal women with HR+/HER2– aBC
aBC, advanced breast cancer; AI, aromatase inhibitor; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone.
Reference
KISQALI® (ribociclib) Summary of Product Characteristics.
UK | January 2026 | FA-11555509
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
